Novartis and Takeda drugs gain rare blood cancer routine use on NHS
Around 200 patients a year will benefit from consolidating the routine use of two marketed drugs for NHS patients with…
20 Jul 2026
Samsung Biologics to acquire PolyPeptide in $1.81bn cash deal
Samsung Biologics is set to acquire PolyPeptide Group through an all-cash public tender offer valued at SFr1.46bn ($1.81bn). The proposed offer is set at SFr44.31 per share for 100% of…
20 Jul 2026
UK biotech financing continues recovery trajectory on five-year Q2 high
After navigating a challenging funding landscape in 2025, the UK biotech sector appears to be in recovery, as per data from the BioIndustry Association (BIA). This comes as UK financing…
20 Jul 2026
Aptar unveils framework for injectable drug delivery systems
Aptar Pharma has launched a collaborative system-level framework designed to support the development of injectable drug delivery systems. The framework will enable pharmaceutical partners to access integrated data packages combining…
17 Jul 2026
Bayer’s heart failure drug bound for NHS on NICE recommendation
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Bayer’s non-steroidal heart failure drug, Kerendia (finerenone), for use in the National Health Service (NHS), as the condition…
17 Jul 2026
FDA grants traditional approval to Novartis’ Fabhalta for IgAN
The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow the decline of kidney function in adults with primary immunoglobulin A nephropathy…
17 Jul 2026
MSD wins FDA approval for cholesterol pill to help plug Keytruda void
MSD (Merck & Co) has won US Food and Drug Administration (FDA) approval for its cholesterol-lowering pill, marking a significant milestone in the drugmaker’s push to reduce revenue reliance on…